Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma.
about
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042.The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indicationsPhase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Cutaneous T-cell lymphoma: a paradigm for biological therapies.Circulating Interferon-Gamma Levels Are Associated with Low Body Weight in Newly Diagnosed Kenyan Non-Substance Using Tuberculosis Individuals.Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.Interferon alpha in lymphoma.Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.Immunological milieu in mycosis fungoides and Sézary syndrome.New and established treatment options for mycosis fungoides and Sézary syndrome - an update.IFN-gamma does not mimic the catabolic effects of TNF-alpha.Cancer cachexia is regulated by selective targeting of skeletal muscle gene productsImmune modulators as therapeutic agents for cutaneous T-cell lymphoma.Prevention of adverse events of interferon γ gene therapy by gene delivery of interferon γ-heparin-binding domain fusion protein in mice.Treatment of cutaneous T-cell lymphoma with alitretinoin gel.Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.Presence of Chlamydophila pneumoniae DNA in blood cells is a frequent event in patients with the late stage of primary cutaneous lymphomas and with atopic dermatitis.Neoplasms
P2860
Q30239965-46FAEF00-035B-48A7-B2C8-B54497C7E60FQ33589409-C8E55D59-75BF-4752-A090-B29B34C9D210Q33746059-868787BF-4AAB-463A-8C3E-8A114E26A446Q33930161-44B0E18D-5471-4EBC-9AE2-31A70C5C081FQ34516083-31D46B16-E8E1-4D43-93DF-167001D233ECQ35821012-9D1215F0-2786-4CB9-AAEA-899581684C6DQ36530288-C2E765AC-BA3A-4AC8-951A-2EC31783E315Q36587700-0F2852D1-19F0-48AA-916A-C9087A52238AQ37422331-DAE61866-66B5-460C-B46B-86ACBFE17096Q37810272-27CC99E7-8AE1-4884-BFB7-2E31829EECF9Q38179489-2FBB2149-E864-4682-991D-332DA443368EQ38216976-48A8B61E-D3D4-45E6-93EE-2EF6056894E9Q40069451-5CC96EEC-3812-4143-9D73-154DE388936AQ40529830-3529E81F-6E15-414A-8D73-778160E152B6Q41844919-EB929709-0C72-4230-B486-13FA7FB3500EQ41987483-23D672AB-E122-4223-92D5-238E0D88CDCFQ43975407-E3166CCE-5B4E-4D69-B54F-BA6EEA8FD6F4Q44328764-A49E5F19-DBC0-4466-9177-332F380B7F59Q55334211-E0017743-0472-412A-B1DC-89BAB50CFA69Q55625429-08D119EE-19A2-475D-8E76-0656F19ECD56Q56828372-6829BE19-5061-44BA-8D3F-039FF3988B80
P2860
Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Phase II study of recombinant ...... of cutaneous T-cell lymphoma.
@en
type
label
Phase II study of recombinant ...... of cutaneous T-cell lymphoma.
@en
prefLabel
Phase II study of recombinant ...... of cutaneous T-cell lymphoma.
@en
P2093
P356
P1476
Phase II study of recombinant ...... of cutaneous T-cell lymphoma.
@en
P2093
P304
P356
10.1093/JNCI/82.3.208
P407
P577
1990-02-01T00:00:00Z